Veriskin develops TruScore, a proprietary, non-invasive hand-held device that combines active perturbative hemodynamic measurements with a proprietary machine-learning algorithm to detect structural and functional vascular abnormalities associated with skin cancer. The device works on both pigmented and non-pigmented lesions and produces a quantitative score; IRB-approved clinical studies in California and Arizona demonstrated sensitivity greater than 99% and specificity of 94% in a set of 125 biopsy-verified lesions. Veriskin has completed two clinical studies and is initiating a third to prepare the clinical trial needed to obtain FDA approval; TruScore received FDA Breakthrough Device Designation in July 2020 and remains investigational and not available for sale. Development has been supported by multiple National Cancer Institute grants totaling $3.9 million (with opportunities for additional funding) alongside private seed capital. The company recently raised over $1M in a seed round co-led by Pasadena Angels and Ariel Savannah Angel Partners, with participation from Frontier Angels and TiE SoCal Angels. Veriskin is headquartered in San Diego and is led by CEO Mirianas Chachisvilis, PhD, with team members across the United States, United Kingdom and Germany.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

May 2021